The online version of this article (doi:10.1186/s13047-017-0195-4) contains supplementary material, which is available to authorized users.
Despite significant advancements in new treatment modalities for rheumatoid arthritis with biological therapies, foot complications remain a disabling and common feature of the disease. In this study the aim was to explore and describe the personal experiences of people with rheumatoid arthritis in receipt of biologic treatments in a bid to understand the impact of this form of medication on their mobility.
An interpretative phenomenological analysis (IPA) was undertaken to explore in depth the individual experience of rheumatoid disease through personal accounts of the patient journey spanning both ‘before’ and ‘after’ the instigation of biologic therapy. A purposive sampling strategy was adopted and in-depth semi structured interviews used to facilitate rich, detailed interview data exploring the lived experiences of individuals undertaking biological therapy and the changes to mobility experienced as a result. Thematic analysis was employed with an IPA framework to identify key meanings, and report patterns within the data.
Five people with rheumatoid arthritis participated in the study. The mean disease duration was 20.2 years (range: 6 -32) and all were being treated with biologic therapies. Four key themes emerged from the data: 1) Life before biologic treatment, depicted in accounts as a negative experience characterised by painful and disabling symptoms and feelings of hopelessness. 2) Life with biologic treatment, often experienced as a life changing transition, restoring function and mobility and offering renewed hope. 3) Sense of self, in which the impact of rheumatoid disease and the subsequent changes arising from biologic therapy reveal a profound impact on feelings of personal identity both pre and post biologic therapy; an effect of footwear on self-image emerges as a dominant sub theme; 4) Unmet footcare needs were evident in the patient narrative, where the unrelenting if diminished impact of foot pain on mobility was viewed in the context of problematic access to foot health services.
Whilst the findings from this study mirror those within the existing literature, which report improvements in physical function related to biological therapy, foot problems clearly remained an unremitting feature of life for patients with rheumatoid disease, even when in receipt of biologics.
Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M, Scott D, Silman A. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford). 2002;41:793–800. CrossRef
Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Tanjong Ghogomu E, Tugwell P. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2009;7(4):CD007848.
Aletaha D, Smolen JS. Remission of rheumatoid arthritis: should we care about definitions? Clin Exp Rheumatol. 2006;24:S-45–51.
van der Leeden M, Steultjens M, Dekker JH, Prins AP, Dekker J. Forefoot joint damage, pain and disability in rheumatoid arthritis patients with foot complaints: the role of plantar pressure and gait characteristics. Rheumatology (Oxford). 2006;45:465–9. CrossRef
Williams AE, Davies S, Graham A, Dagg A, Longrigg K, Lyons C, Bowen C. Guidelines for the management of the foot health problems associated with rheumatoid arthritis. Musculoskeletal Care. 2011;9(2):86–92.
Marshall NJ, Wilson G, Lapworth K, Kay LJ. Patients’ perceptions of treatment with anti-TNF therapy for rheumatoid arthritis: a qualitative study. Rheumatology (Oxford). 2004;43:1034–8. CrossRef
Smith AJ, Flowers P, Larkin M. Interpretative Phenomenolical Analysis. London: Sage; 2009.
Williams SJ. Chronic illness as biographical disruption of biographical disruption as chronic illness? Reflections on a core concept. Sociol Health Illn. 2000;22:40–67. CrossRef
Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care. 2008;14:234–54. PubMed
ARMA. Standards of Care for people with Musculoskeletal Foot Health Problems. UK: The Arthritis and Musculoskeletal Alliance; 2004.
NICE. Rheumatoid arthritis in adults (CG79): management (Health ed). London: The National Institute for Health and Clinical Excellence; 2009.
Rome K, Erikson K, Ng A, Gow PJ, Sahid H, Williams AE. A new podiatry service for patients with arthritis. N Z Med J. 2013;126:70–7. PubMed
- Experiences of mobility for people living with rheumatoid arthritis who are receiving biologic drug therapy: implications for podiatry services
Catherine J. Bowen
- BioMed Central
Neu im Fachgebiet Orthopädie und Unfallchirurgie
Mail Icon II